QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Forecast, Price & News

$2.01
0.00 (0.00%)
(As of 10/2/2023 ET)
Compare
Today's Range
$2.00
$2.04
50-Day Range
$2.00
$2.07
52-Week Range
$1.85
$2.70
Volume
36,431 shs
Average Volume
26,261 shs
Market Capitalization
$28.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

ABIO Price History

ABIO Stock News Headlines

How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
ABIO - ARCA biopharma, Inc.
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
7/21/2023
Today
10/02/2023
Next Earnings (Estimated)
10/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
5
Year Founded
N/A

Profitability

Net Income
$-9,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
N/A
Market Cap
$29.11 million
Optionable
Not Optionable
Beta
1.30
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Michael R. Bristow M.D. (Age 78)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $358.8k
  • Mr. Thomas A. Keuer (Age 64)
    Chief Operating Officer
    Comp: $360.59k
  • Mr. C. Jeffrey Dekker CPA (Age 58)
    Chief Financial Officer













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 at the beginning of 2023. Since then, ABIO stock has decreased by 14.8% and is now trading at $2.02.
View the best growth stocks for 2023 here
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 265,000 shares, an increase of 9.5% from the August 31st total of 242,000 shares. Based on an average daily volume of 20,600 shares, the days-to-cover ratio is currently 12.9 days. Approximately 1.9% of the company's stock are sold short.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) posted its earnings results on Friday, July, 21st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.02.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $29.11 million. The biopharmaceutical company earns $-9,930,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -